See below; an article dated 25 Sep 2019 (source of this news: Muscular Dystrophy News today_News letter)

Think before you buy BLT and analyse share trading trend of BLT:

People are accumulating this stock. See buying trend for the last coupe of days. It is expected BLT would shoot-up to 0.25 c or more as soon as the announcement is made in coming weeks.
This gene therapy would be the first of its kind if successful! That is why BLT has potential to be $1 billion company! Investors may not believe it for now but it seems BLT is in the making!

Final Tests Planned into Potential Gene Therapy for OPMD, Could Support Trial in Patients

Three new animal-model tests of a potential gene therapy for oculopharyngeal muscular dystrophy (OPMD), known as BB-301, are planned, Benitec Biopharma announced. Results are expected to support a request for a Phase 1 clinical trial in patients.

OPMD results from a faulty PABPN1 gene, leading to a protein that can form insoluble clumps linked with muscle weakness.

BB-301 uses a DNA-directed RNA interference (ddRNAi) strategy. Delivered via a modified, harmless adeno-associated virus (AAV), the therapy is intended to “silence and replace” the mutant protein. It suppresses its production and provides a source of normal, or wild-type, protein to target cells.

For further information for reliability and accuracy, see hyper-link below

https://musculardystrophynews.com/2019/09/25/final-tests-planned-for-bb-301-opmd-gene-therapy-could-support-phase-1-trial/